Positron emission tomography in malignancies of the liver, pancreas and biliary tract – indications and potential pitfalls

References

• Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008;14:4300–8.
   PubMed Web of Science ®Google Scholar
• Liu PS, Francis IR. Hepatic imaging for metastatic disease. Cancer J 2010;16:93–102.
   PubMed Web of Science ®Google Scholar
• de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999;341:1368–78.
   PubMed Web of Science ®Google Scholar
• Wolpin BM, Mayer RJ. A step forward in the treatment of advanced biliary tract cancer. N Engl J Med 2010;362:1335–7.
   PubMed Web of Science ®Google Scholar
• Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605–17.
   PubMed Web of Science ®Google Scholar
• Mossner J. What's new in therapy of pancreatic cancer? Dig Dis 2010;28:679–83.
   PubMed Web of Science ®Google Scholar
• Syrota A, Duquesnoy N, Paraf A, Kellershohn C. The role of positron emission tomography in the detection of pancreatic disease. Radiology 1982;143:249–53.
   PubMed Web of Science ®Google Scholar
• Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004;231:305–32.
   PubMed Web of Science ®Google Scholar
• Garcea G, Ong SL, Maddern GJ. The current role of PET-CT in the characterization of hepatobiliary malignancies. HPB (Oxford) 2009;11:4–17.
   PubMed Web of Science ®Google Scholar
• Lin EG, Alavi A. PET and PET/CT: a clinical guide. New York, NY: Thieme; 2005.
   Google Scholar
• Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999;94:3314–19.
   PubMed Web of Science ®Google Scholar
• Lin CY, Chen JH, Liang JA, Lin CC, Jeng LB, Kao CH. 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis. Eur J Radiol 2011. [Epub ahead of print]
   Web of Science ®Google Scholar
• Sugiyama M, Sakahara H, Torizuka T, Kanno T, Nakamura F, Futatsubashi M, 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 2004;39:961–8.
   PubMed Web of Science ®Google Scholar
• Kim HO, Kim JS, Shin YM, Ryu JS, Lee YS, Lee SG. Evaluation of metabolic characteristics and viability of lipiodolized hepatocellular carcinomas using 18F-FDG PET/CT. J Nucl Med 2010;51:1849–56.
   PubMed Web of Science ®Google Scholar
• Cascales Campos P, Ramirez P, Gonzalez R, Febrero B, Pons JA, Miras M, Value of 18-FDG-positron emission tomography/computed tomography before and after transarterial chemoembolization in patients with hepatocellular carcinoma undergoing liver transplantation: initial results. Transplant Proc 2011;43:2213–15.
   PubMed Web of Science ®Google Scholar
• Lee JH, Park JY, Kim DY, Ahn SH, Han KH, Seo HJ, Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Liver Int 2011;31:1144–9
   PubMed Web of Science ®Google Scholar
• Kitamura K, Hatano E, Higashi T, Seo S, Nakamoto Y, Yamanaka K, Preoperative FDG-PET predicts recurrence patterns in hepatocellular carcinoma. Ann Surg Oncol 2012;19:156–62
   PubMed Web of Science ®Google Scholar
• Kornberg A, Kupper B, Tannapfel A, Buchler P, Krause B, Witt U, Patients with (18) F-FDG non-avid advanced HCC on clinical staging may achieve recurrence-free long-term survival after liver transplantation. Liver Transpl 2012;18:53–61
   PubMed Web of Science ®Google Scholar
• Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002;224:748–56.
   PubMed Web of Science ®Google Scholar
• Kong G, Jackson C, Koh DM, Lewington V, Sharma B, Brown G, The use of 18F-FDG PET/CT in colorectal liver metastases--comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging 2008;35:1323–9.
   PubMed Web of Science ®Google Scholar
• Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 2005;104:2658–70.
   PubMed Web of Science ®Google Scholar
• Huguet EL, Old S, Praseedom RK, Balan KK, Gibbs P, Jamieson NV. F18-FDG-PET evaluation of patients for resection of colorectal liver metastases. Hepatogastroenterology 2007;54:1667–71.
   PubMedGoogle Scholar
• Patel S, McCall M, Ohinmaa A, Bigam D, Dryden DM. Positron emission tomography/computed tomographic scans compared to computed tomographic scans for detecting colorectal liver metastases: a systematic review. Ann Surg 2011;253:666–71.
   PubMed Web of Science ®Google Scholar
• Lubezky N, Metser U, Geva R, Nakache R, Shmueli E, Klausner JM, The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg 2007;11:472–8.
   PubMed Web of Science ®Google Scholar
• Kuehl H, Antoch G, Stergar H, Veit-Haibach P, Rosenbaum-Krumme S, Vogt F, Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: initial results. Eur J Radiol 2008;67:362–71.
   PubMed Web of Science ®Google Scholar
• Sahin DA, Agcaoglu O, Chretien C, Siperstein A, Berber E. The utility of PET/CT in the management of patients with colorectal liver metastases undergoing laparascopic radiofrequency thermal ablation. Ann Surg Oncol 2012;19:850–5
   PubMed Web of Science ®Google Scholar
• Hueman MT, Vollmer CM Jr, Pawlik TM. Evolving treatment strategies for gallbladder cancer. Ann Surg Oncol 2009;16:2101–15.
   PubMed Web of Science ®Google Scholar
• Lee SW, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. J Gastroenterol 2010;45:560–6.
   PubMed Web of Science ®Google Scholar
• Petrowsky H, Wildbrett P, Husarik DB, Hany TF, Tam S, Jochum W, Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006;45:43–50.
   PubMed Web of Science ®Google Scholar
• Shukla PJ, Barreto SG, Arya S, Shrikhande SV, Hawaldar R, Purandare N, Does PET-CT scan have a role prior to radical re-resection for incidental gallbladder cancer? HPB (Oxford) 2008;10:439–45.
   PubMed Web of Science ®Google Scholar
• Corvera CU, Blumgart LH, Akhurst T, DeMatteo RP, D'Angelica M, Fong Y, 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 2008;206:57–65.
   PubMed Web of Science ®Google Scholar
• Kim JY, Kim MH, Lee TY, Hwang CY, Kim JS, Yun SC, Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol 2008;103:1145–51.
   PubMed Web of Science ®Google Scholar
• Kato T, Tsukamoto E, Kuge Y, Katoh C, Nambu T, Nobuta A, Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging 2002;29:1047–54.
   PubMed Web of Science ®Google Scholar
• Wakabayashi H, Akamoto S, Yachida S, Okano K, Izuishi K, Nishiyama Y, Significance of fluorodeoxyglucose PET imaging in the diagnosis of malignancies in patients with biliary stricture. Eur J Surg Oncol 2005;31:1175–9.
   PubMed Web of Science ®Google Scholar
• Breitenstein S, Apestegui C, Clavien PA. Positron emission tomography (PET) for cholangiocarcinoma. HPB (Oxford) 2008;10:120–1.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Yun M, Lee WJ, Kim KS, Lee JD. Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging 2003;30:1467–72.
   PubMed Web of Science ®Google Scholar
• Li J, Kuehl H, Grabellus F, Muller SP, Radunz S, Antoch G, Preoperative assessment of hilar cholangiocarcinoma by dual-modality PET/CT. J Surg Oncol 2008;98:438–43.
   PubMed Web of Science ®Google Scholar
• Reinhardt MJ, Strunk H, Gerhardt T, Roedel R, Jaeger U, Bucerius J, Detection of Klatskin's tumor in extrahepatic bile duct strictures using delayed 18F-FDG PET/CT: preliminary results for 22 patient studies. J Nucl Med 2005;46:1158–63.
   PubMed Web of Science ®Google Scholar
• Moon CM, Bang S, Chung JB, Park SW, Song SY, Yun M, Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. J Gastroenterol Hepatol 2008;23:759–65.
   PubMed Web of Science ®Google Scholar
• Ruys AT, Bennink RJ, van Westreenen HL, Engelbrecht MR, Busch OR, Gouma DJ, FDG-positron emission tomography/computed tomography and standardized uptake value in the primary diagnosis and staging of hilar cholangiocarcinoma. HPB (Oxford) 2011;13:256–62.
   PubMed Web of Science ®Google Scholar
• Jadvar H, Fischman AJ. Evaluation of pancreatic carcinoma with FDG PET. Abdom Imaging 2001;26:254–9.
   PubMedGoogle Scholar
• Keogan MT, Tyler D, Clark L, Branch MS, McDermott VG, DeLong DM, Diagnosis of pancreatic carcinoma: role of FDG PET. AJR Am J Roentgenol 1998;171:1565–70.
   PubMed Web of Science ®Google Scholar
• Andersson R, Vagianos CE, Williamson RC. Preoperative staging and evaluation of resectability in pancreatic ductal adenocarcinoma. HPB (Oxford) 2004;6:5–12.
   PubMedGoogle Scholar
• Kauhanen SP, Komar G, Seppanen MP, Dean KI, Minn HR, Kajander SA, A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg 2009;250:957–63.
   PubMed Web of Science ®Google Scholar
• Okano K, Kakinoki K, Akamoto S, Hagiike M, Usuki H, Yamamoto Y, 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of small pancreatic cancer. World J Gastroenterol 2011;17:231–5.
   PubMed Web of Science ®Google Scholar
• Heinrich S, Goerres GW, Schafer M, Sagmeister M, Bauerfeind P, Pestalozzi BC, Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 2005;242:235–43.
   PubMed Web of Science ®Google Scholar
• Ruf J, Lopez Hanninen E, Oettle H, Plotkin M, Pelzer U, Stroszczynski C, Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology 2005;5:266–72.
   PubMed Web of Science ®Google Scholar
• Schellenberg D, Quon A, Minn AY, Graves EE, Kunz P, Ford JM, 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 2010;77:1420–5.
   PubMed Web of Science ®Google Scholar
• Goh BK, Chung YF, Ng DC, Selvarajan S, Soo KC. Positron emission tomography with 2-deoxy-2-[18f] fluoro-D-glucose in the detection of malignancy in intraductal papillary mucinous neoplasms of the pancreas. JOP 2007;8:350–4.
   PubMedGoogle Scholar
• Tomimaru Y, Takeda Y, Tatsumi M, Kim T, Kobayashi S, Marubashi S, Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas. Oncol Rep 2010;24:613–20.
   PubMed Web of Science ®Google Scholar
• Balci NC, Semelka RC. Radiologic diagnosis and staging of pancreatic ductal adenocarcinoma. Eur J Radiol 2001;38:105–12.
   PubMed Web of Science ®Google Scholar
• Kajiwara M, Kojima M, Konishi M, Nakagohri T, Takahashi S, Gotohda N, Autoimmune pancreatitis with multifocal lesions. J Hepatobiliary Pancreat Surg 2008;15:449–52.
   PubMedGoogle Scholar
• Kamisawa T, Takum K, Anjiki H, Egawa N, Kurata M, Honda G, FDG-PET/CT findings of autoimmune pancreatitis. Hepatogastroenterology 2010;57:447–50.
   PubMedGoogle Scholar
• Nakajo M, Jinnouchi S, Fukukura Y, Tanabe H, Tateno R. The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and associated extrapancreatic autoimmune lesions. Eur J Nucl Med Mol Imaging 2007;34:2088–95.
   PubMed Web of Science ®Google Scholar
• Lee TY, Kim MH, Park do H, Seo DW, Lee SK, Kim JS, Utility of 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer. AJR Am J Roentgenol 2009;193:343–8.
   PubMed Web of Science ®Google Scholar
• Pisters PW, Lee JE, Vauthey JN, Charnsangavej C, Evans DB. Laparoscopy in the staging of pancreatic cancer. Br J Surg 2001;88:325–37.
   PubMed Web of Science ®Google Scholar
• Ruys AT, Busch OR, Gouma DJ, van Gulik TM. Staging laparoscopy for hilar cholangiocarcinoma: is it still worthwhile? Ann Surg Oncol 2011;18:2647–53.
   PubMed Web of Science ®Google Scholar
• Tapper E, Kalb B, Martin DR, Kooby D, Adsay NV, Sarmiento JM. Staging laparoscopy for proximal pancreatic cancer in a magnetic resonance imaging-driven practice: what's it worth? HPB (Oxford) 2011;13:732–7.
   PubMed Web of Science ®Google Scholar
• Hariharan D, Constantinides V, Kocher HM, Tekkis PP. The role of laparoscopy and laparoscopic ultrasound in the preoperative staging of patients with resectable colorectal liver metastases: a meta-analysis. Am J Surg 2012;204:84–92
   PubMed Web of Science ®Google Scholar
• Wiering B, Adang EM, van der Sijp JR, Roumen RM, de Jong KP, Comans EF, Added value of positron emission tomography imaging in the surgical treatment of colorectal liver metastases. Nucl Med Commun 2010;31:938–44.
   PubMed Web of Science ®Google Scholar